For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Where to buy · live market data

Who's worth your money for Tesamorelin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 28 scored sellers

$3.40/mg

$67.99 · 20mg · 99.8% purity

13 COAs
Buy code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$3.50/mg

$700 · 200mg · 98.9% purity

Most tested

28 independent COAs on file

$4.49/mg

$898 · 200mg · 99.8% purity

Average price

$8.68/mg

Sellers

88

45-day trend

-19.1%

76 of 88 sellers have a current price· 21 stale hidden· 27 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tesamorelin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tesamorelin

CAS

218949-48-5

Molecular formula

C221H366N72O67S

Sequence

YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL

Typical dose range

2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC

Half-life

~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)

Independent evidence

COAs for Tesamorelin

260 third-party tests across 38 vendors. Each card links to the full report.

All 260 COAs for Tesamorelin →
Measured purity 98.0%–100.0% across 148 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM-13

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Optima Supply· batch OS-2026-1763

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Hydro Research Peptides· batch HR-2026-4509

Aggregated · 3rd-party listing
99.97 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch tsm20-04

Aggregated · 3rd-party listing
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Profound Aminos· batch Black Cap

✓ Vendor-published
99.83 %
Jun 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch TES202607

COA on file
Aggregated · 3rd-party listing
99.89 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10-06022026

Aggregated · 3rd-party listing
99.81 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 136-02-SM-WT

Aggregated · 3rd-party listing
99.37 %
Jun 2026
Horizon Analytical

For

Tesamorelin

by Blank Peptides· batch B-3699671-P

Aggregated · 3rd-party listing
99.78 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10.05.28.26

Aggregated · 3rd-party listing
99.26 %
Jun 2026
Janoshik Analytical Limited

For

Tesamorelin

by Verified Peptides· batch TM07261020J

✓ Vendor-published
99.89 %
Jun 2026
ILS Laboratories

For

Tesa

by Ion Peptide· batch TSM10-06022026

COA on file
✓ Vendor-published
99.71 %
May 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch SPL-3947

COA on file
Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics Strong · HPLC

For

Tesamorelin

by OROS Research· batch OR-LPTES5-526-B6

✓ Vendor-published
99.82 %
May 2026
Kovera Labs

For

Tesamorelin

by Ion Peptide· batch TSM20-05142026

COA on file
Aggregated · 3rd-party listing
99.77 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Glacier Aminos· batch TES10GA-07

Aggregated · 3rd-party listing
99.47 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Crush Research· batch CR-TSM20-0307-1

Aggregated · 3rd-party listing
99.24 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-10-002

Aggregated · 3rd-party listing
99.23 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-004

✓ Vendor-published
99.02 %
May 2026
Vanguard Laboratory Strong

For

Tesamorelin/Ipamorelin

by Licensed Peptides· batch Green Cap

COA on file
Aggregated · 3rd-party listing
99.48 %
May 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM20-3

✓ Vendor-published
99.43 %
May 2026
FreedomDiagnosticsTesting.com

For

Tesamorelin

by Forge Performance Co.· batch Clear Blue Cap

COA on file
Aggregated · 3rd-party listing
99.78 %
May 2026
ILS Labs Strong

For

Tesamorelin

by Ion Peptide· batch TSM10-05042026

✓ Vendor-published
99.78 %
May 2026
ILS Laboratories

For

Tesamorelin

by Ion Peptide· batch TSMH10-0504206

COA on file
Research depth

23 citations indexed for Tesamorelin

All research on Tesamorelin →

Study · 2026

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol

Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

meta-analysis · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants